vida: extract claims from 2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025

- Source: inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md

@@ -31,3 +31,10 @@ Exenatide Phase 3 showed no DaT-SPECT signal change versus placebo, meaning the
 **Source:** Holscher 2024 review + exenatide Phase 3 CSF data (Lancet Feb 2025)
 
 Exenatide Phase 3 CSF analysis revealed that BBB crossing (a pharmacokinetic surrogate) doesn't predict substantia nigra penetrance (the therapeutic target). Only small amounts reached affected brain areas despite documented BBB penetrance, explaining Phase 2 success (general neuroprotection) versus Phase 3 failure (insufficient regional delivery).
+
+
+## Supporting Evidence
+
+**Source:** PMC12374370 meta-analysis 2025
+
+Updated meta-analysis (5 RCTs, n=708) shows MDS-UPDRS Part III improvement of only -2.06 points (95% CI -4.09 to -0.03)—statistically significant but clinically marginal. No improvement in MDS-UPDRS Parts I, II, IV, no levodopa dose reduction, no PDQ-39 quality of life improvement, and no Non-Motor Symptoms Scale improvement. This confirms that motor biomarker changes do not translate to functional benefit in Parkinson's GLP-1 trials.

domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md

@@ -38,3 +38,10 @@ GLP-1 receptor expression in ventral tegmental area (VTA) and nucleus accumbens
 **Source:** LIXIPARK NEJM April 2024
 
 LIXIPARK demonstrated motor symptom stabilization in early Parkinson's disease (dopaminergic neurodegeneration) at 12 months, challenging the blanket claim that GLP-1s fail in neurodegeneration. However, this is Phase 2 in early disease only, and the lack of Phase 3 funding post-publication suggests the field remains skeptical. The divergence from exenatide Phase 3 failure indicates disease stage and drug-specific penetrance may be boundary conditions.
+
+
+## Extending Evidence
+
+**Source:** PMC12374370 + Lancet exenatide Phase 3 Feb 2025
+
+Exenatide Phase 3 failure (Lancet Feb 2025) with CSF analysis showing BBB crossing but insufficient substantia nigra penetrance provides mechanistic explanation: GLP-1 agonists succeed in reward circuits (VTA, nucleus accumbens) but fail in neurodegeneration (substantia nigra) due to regional CNS access differences, not circuit-specific receptor distribution. Lixisenatide Phase 2 success suggests within-class variation in regional penetrance.

entities/health/most-able-trial.md

@@ -0,0 +1,39 @@
+---
+type: entity
+entity_type: research_program
+name: MOST-ABLE Trial
+full_name: Oral Semaglutide for Parkinson's Disease Motor Symptoms Trial
+domain: health
+status: active
+---
+
+# MOST-ABLE Trial
+
+**Type:** Phase 2/3 randomized controlled trial  
+**Intervention:** Oral semaglutide 7mg and 14mg daily  
+**Population:** n=99 patients with Parkinson's disease  
+**Location:** Japan  
+**Primary Endpoint:** Motor symptom improvement (MDS-UPDRS Part III)  
+
+## Overview
+
+MOST-ABLE is the first randomized controlled trial testing semaglutide specifically for Parkinson's disease motor symptoms. Unlike prior GLP-1 Parkinson's trials (exenatide, liraglutide, lixisenatide), this study uses oral semaglutide, which has a distinct CNS access mechanism via tanycytes targeting hypothalamus and brainstem regions.
+
+## Significance
+
+The trial addresses a critical evidence gap: all prior GLP-1 Parkinson's RCTs used older GLP-1 agonists with different CNS penetrance profiles. Exenatide's Phase 3 failure (Lancet Feb 2025) revealed that blood-brain barrier crossing does not guarantee substantia nigra penetrance. Semaglutide's tanycyte-mediated CNS access may provide superior regional distribution, but this remains empirically unproven.
+
+## Timeline
+
+- **2024** — Protocol published, enrollment completed
+- **Nov-Dec 2025** — Data collection completed
+- **2026** — Results expected (as of May 2026, publication pending)
+
+## Context
+
+Meta-analysis of 5 prior GLP-1 Parkinson's RCTs (n=708) shows narrow motor benefit (MDS-UPDRS Part III -2.06, 95% CI -4.09 to -0.03) but no functional quality of life improvement. MOST-ABLE results will determine whether semaglutide's distinct CNS access mechanism translates to superior clinical efficacy.
+
+## Sources
+
+- PMC12374370 meta-analysis (Jan 2025)
+- Session 40 GLP-1 Parkinson's divergence analysis (May 2026)

inbox/archive/health/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: research
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-09
 priority: medium
 tags: [GLP-1, Parkinson's-disease, meta-analysis, semaglutide, exenatide, lixisenatide, neuroprotection, motor-symptoms]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content